Abstract: The present invention provides macrocyclic compounds useful as therapeutic agents of the formula: or a pharmaceutically acceptable salt, ester, N-oxide, or prodrug thereof, wherein T, R1, R2, R3, D, E, F, and G are as defined herein. More particularly, these compounds are useful as anti-infective, antiproliferative, anti-inflammatory and prokinetic agents.

Abstract: Disclosed is a method for preparing polysaccharides of green tea, and more particularly to a method for preparing polysaccharides of green tea comprising the steps of: a) removing chlorophyll and a low molecular weight polyphenol from green tea powder using a solvent; b) hot-water extracting a water-soluble active ingredient from the green tea residue of step a); and c) separating the polysaccharides of green tea from the hot-water extract of step b) by ultrafiltration and ethanol precipitation. Also, the present invention relates to a cosmetic composition for skin whitening, moisturization and anti-wrinkle effects comprising the polysaccharides of green tea as an effective ingredient.

Abstract: Provided herein are conjugates comprising a protein and an oligosaccharide of one of Formulae I-VI. Also provided herein are pharmaceutical compositions comprising such conjugates. Further provided herein are methods of treating a lysosomal storage disorder in a mammal by administration of an oligosaccharide-glycoprotein conjugate.

Abstract: Foliamngiferosides having the general formula (I) are disclosed, wherein R is H or —OCH. The preparation method of the compounds, pharmaceutical compositions comprising the compounds as the active ingredients, the use of the compounds and the pharmaceutical compositions for inhibiting the activity of ?-glucosidase are also disclosed. The foliamangiferosides can be used in preparing drugs for treating diabetes.

Abstract: Procedure for the synthesis of deprotected pentasaccharides from a protected precursor pentasaccharide through a reaction procedure having five stages whereamong is included an N-sulphation of amino groups and a hydrogenolysis of benzyl groups. Through this procedure a drastic reduction is achieved in the total synthesis time in comparison with the process traditionally employed, together with increased reproducibility thereof, permitting the standardization thereof.

Abstract: The present invention is directed to hemostatic material containing compacted ORC powder comprising particles having an average aspect ratio from about 1 to about 18, wherein said compacted ORC powder have preferably been processed in a compaction device, such as a ball milled ORC powder. The present invention further relates to methods of making the hemostatic material and a method of treating a wound by applying the hemostatic powder onto and/or into the wound of a patient.

Abstract: The present invention provides a method of preparing a glycoside of a mono- or diacylglycerol product from a plant material. The method comprises the steps of: (i) optionally milling the plant material, (ii) extracting the optionally milled plant material with a first aqueous extraction solution obtaining a first liquid phase and a first solid phase, (iii) separating the liquid phase from the solid phase to obtain a glycoside of mono- or diacylglycerol product, (iv) extracting the solid phase from step (iii) with a second extraction solution obtaining a second liquid phase and a second phase, and (v) separating the second liquid phase from the second solid phase to obtain a second and a third glycoside of mono- or diacylglycerol product, wherein the second extraction solution further comprises a cell wall degrading enzyme or a mixture of cell wall degrading enzymes.

Abstract: Dispersions that comprise insoluble alginate/gelling ion particles in an alginate solution, wherein the dispersion exhibits less than 10% of final gel storage modulus after one minute in the absence of addition of non-gelling cations are disclosed. Kits and compositions for making such dispersions are disclosed and methods for making and using the dispersions, and the components used in the dispersions are also disclosed.

Abstract: Disclosed is a process for the production of d-tagatose from lactose after acid hydrolysis to provide a hydrolysate having 1 equiv of d-glucose and 1 equiv of d-galactose for each unit of lactose converted. More particularly, the invention relates to a process for the isomerization of d-galactose to d-tagatose and the use of a simplified separation scheme based on simulated moving bed (SMB) separation. The isomerization of d-galactose to d-tagatose is carried out in the presence of calcium oxide or calcium hydroxide. The process is useful for providing a simplified processing route to providing pure d-tagatose and glucose as two products from lactose hydrolysate. In an alternate embodiment, a process is disclosed for the production of d-tagatose from fermented lactose hydrolysate to provide a crystallized d-tagatose product. D-tagatose is useful as a food additive, as a sweetener, as a texturizer, as a stabilizer, or as a humectant.

Abstract: The invention relates to a method for the preparation for a crystalline form of 1-chloro-4-(?-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene. In addition the invention relates to a crystalline form obtainable by this method, to a pharmaceutical composition and to the use thereof for preparing medicaments.

Abstract: Esterification of a carbohydrate using an acylating agent can effectively be performed using a process comprising: (a) combining the carbohydrate with the acylating agent, (b) adjusting the moisture content of the combination below 40 wt. %, and (c) subjecting the combination to superheated steam. The carbohydrate is especially starch and the acylating agent is in particular an acid, such as an organic acid, amino acid, or diacid.

Abstract: A compound of the formula: wherein Ring A and Ring B are: (1) Ring A is an optionally substituted unsaturated monocyclic heterocyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring, (2) Ring A is an optionally substituted benzene ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring or an optionally substituted unsaturated fused heterobicyclic ring, or (3) Ring A is an optionally substituted unsaturated fused heterobicyclic ring, and Ring B are independently an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring; X is a carbon atom or a nitrogen atom; Y is —(CH2)n— (n is 1 or 2); or a pharmaceutically acceptable salt thereof, or a prodrug thereof.

Abstract: The invention relates to crystalline hydrates of the formula I in which n has a value of from 2.1 to 2.5. The compound is suitable, for example, as an antidiabetic.

Abstract: The present invention includes methods for the treatment of autoimmune disorders such as autism, schizophrenia, and type 1 diabetes. Flavonoids, luteolin, diosmin, and diosmin's aglycone form, diosmetin, were found to inhibit activation/phosphorylation of STAT3 induced by IL-6 in cultured neuronal cells. Furthermore, mice treated with diosmin showed a significant reduction of autistic phenotype induced by IL-6 through inhibition of STAT3 activation.

Abstract: The invention provides small molecule drugs that are chemically modified by covalent attachment of a water-soluble oligomer.

Abstract: The present invention relates to the medical field. In a first aspect the present invention relates to novel water soluble cyclodextrin-curcumin complexes having a pharmacological activity, in particular an anti-tumor and/or anti-inflammatory activity, and improved physico-chemical properties. In a second aspect, the present invention relates to a method for preparation of said water soluble curcumin derivatives. The invention further relates in a third aspect to a pharmaceutical composition comprising an effective amount of said water soluble curcumin derivatives. In a fourth aspect, the present invention concerns the use of said water soluble cucumin derivatives as a medicament and the use of said water soluble curcumin derivatives for the preparation of a medicament for the treatment of cancer and inflammatory diseases.

Abstract: Disclosed herein are cyclic nucleotide analogs, methods of synthesizing cyclic nucleotide analogs and methods of treating diseases and/or conditions such as viral infections, cancer, and/or parasitic diseases with cyclic nucleotide analogs.

Abstract: Disclosed are a novel fluorescent glucose analogue, a method for the synthesis thereof and the use thereof. The novel fluorescent glucose analogue is labeled with fluorescent dye by O-1-glycosylation and via various linkers. The fluorescent glucose analogue can be applied to molecular bioimaging and a method for screening curative or preventive drugs for glucose metabolism-related diseases.

Abstract: The present invention is directed to a crosslinked or non-crosslinked polymer particle, wherein the crosslinked polymer particle comprises a copolymer of poly(alklyene glycol-graft-acrylate) that is crosslinked by at least one hydrolysable monomer or crosslinking agent. The present invention is also directed to a polymer particle comprising a crosslinked polymer particle that is a product of starting materials comprising (a) a hydrophilic monomer, (b) a hydrophobic monomer, and (c) a hydrolysable crosslinking agent (the crosslinking agent may be absent in the case of non-crosslinked particles). The present invention is still further directed to a polymer particle comprising a crosslinked copolymer, where the crosslinked copolymer includes structures represented by Formulas (I), (II), and (III), as defined in the specification. Other embodiments of the present invention also include methods of manufacturing polymer particles.

Abstract: The present invention relates to the formulations of ester derivatives of capsaicin and ester derivatives of myristoleic acid. These derivatives are capable of reverting to the active parent compound following enzymatic or chemical hydrolysis. These derivatives have a higher lipophilicity, lipid solubility and less irritation to the skin than the parent compound, and hence are better able to be incorporated into certain pharmaceutical formulations, including cream and ointment pharmaceutical formulations. The pharmaceutical compositions are useful for pain management in mammals in vivo and have been contemplated to be used in the treatment of various pains in humans.